UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 7, 2011
SYMBOLLON PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
|
Delaware
|
0-22872
|
36-3463683
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer Identification No.)
|
99 West Street, Suite J, Medfield, Massachusetts 02052
(Address of principal executive offices) (Zip Code)
(508) 242-7500
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13-4(c))
|
Item 4.01 Changes in Registrant’s Certifying Accountant.
Engagement of New Independent Registered Public Accounting Firm.
|
i
|
On March 2, 2011, the Board of Directors appointed Sam Kan & Company (“Sam Kan”) as the Company’s new independent registered public accounting firm. The decision to engage Sam Kan was approved by the Company’s Board of Directors on March 7, 2011.
|
|
ii
|
Prior to March 7, 2011, the Company did not consult with Sam Kan regarding (1) the application of accounting principles to a specified transactions, (2) the type of audit opinion that might be rendered on the Company’s financial statements, (3) written or oral advice was provided that would be an important factor considered by the Company in reaching a decision as to an accounting, auditing or financial reporting issues, or (4) any matter that was the subject of a disagreement between the Company and its predecessor auditor as described in Item 304(a)(1)(iv) or a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
March 24, 2011
|
SYMBOLLON PHARMACEUTICALS, INC.
|
|
By: /s/ Paul C. Desjourdy
|
|
|
Paul C. Desjourdy
|
|
|
President, Chief Executive Officer and Chief Financial Officer
|
2